Immunotherapeutic approaches to ovarian cancer treatment

Abstract

J Immunother Cancer. 2015 Mar 24;3:7. doi: 10.1186/s40425-015-0051-7. eCollection 2015.

Immunotherapeutic approaches to ovarian cancer treatment.
Chester C1, Dorigo O2, Berek JS2, Kohrt H1.
Author information
    1Department of Medicine, Division of Oncology, Stanford University School of Medicine, Stanford, CA USA.
    2Stanford Women's Cancer Center, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Stanford University School of Medicine, Stanford, CA 94305 U.S.A.

Abstract
Despite advances in combinatorial chemotherapy regimens and the advent of intraperitoneal chemotherapy administration, current therapeutic options for ovarian cancer patients are inadequate. Immunotherapy offers a novel and promising therapeutic strategy for treating ovarian tumors. Following the demonstration of the immunogenicity of ovarian tumors, multiple immunotherapeutic modalities have been developed. Antibody-based therapies, immune checkpoint blockade, cancer vaccines, and chimeric antigen receptor-modified T cells have demonstrated preclinical success and entered clinical testing. In this review, we discuss these promising immunotherapeutic approaches and emphasize the importance of combinatorial treatment strategies and biomarker discovery.

KEYWORDS:

ACT; Antibody; Cancer vaccine; ID8; IDO; Immune checkpoint blockade; Ovarian cancer; TAM